Study guide

6.2 Insulin Formulations, Concentrations (U-100, U-500, U-200, U-300), and Pen/Vial Math

PTCB Technician Product Verification TPV

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Tech-Check-Tech Verification Fundamentals

1.1 About the PTCB TPV Certificate Exam 1.2 Tech-Check-Tech (TCT) Scope, Regulations, and Quality Assurance 1.3 Systematic Verification Protocol & Visual Inspection Steps

2 Chapter 2: Drug Name Verification & Brand/Generic Identification

2.1 Brand vs Generic Mapping, USAN Stems, and Orange Book Therapeutic Equivalence 2.2 Salt Forms and Active Ingredient Verification 2.3 Manufacturer-Specific Identification, Visual Cues, and Color Codes

3 Chapter 3: Auxiliary Labels, REMS & Controlled Substances

3.1 Auxiliary Warning Labels and Mandatory Patient Counseling Triggers 3.2 REMS Programs and Restricted Distribution Medications 3.3 Controlled Substance Scheduling, Refill Restrictions, and C-II Exact Counts

4 Chapter 4: Dosage Forms, Release Mechanisms & Administration Routes

4.1 Modified-Release Formulations (ER, XL, SR, DR, CR) and "Do Not Crush" Rules 4.2 Route of Administration Verification: Ophthalmic vs Otic, Oral vs Topical vs Transdermal 4.3 Specialized Delivery Systems: Inhalers (MDI/DPI), ODTs, Solutions vs Suspensions

5 Chapter 5: Strength Verification & Pharmaceutical Calculations

5.1 Unit Conversions (mcg, mg, g) and Preventing Leading/Trailing Zero Errors 5.2 Percentage Strengths, Ratio Strengths, and Liquid Concentrations (mg/mL) 5.3 Electrolyte Equivalents (mEq vs mg) and Combination Product Strength Verification

6 Chapter 6: High-Alert Medications & Safety Protocols

6.1 ISMP High-Alert Medications and Independent Double-Check Protocols 6.2 Insulin Formulations, Concentrations (U-100, U-500, U-200, U-300), and Pen/Vial Math 6.3 Concentrated Electrolytes, Opioids, Neuromuscular Blockers, and Oral Methotrexate

7 Chapter 7: Look-Alike / Sound-Alike (LASA) Medications

7.1 FDA and ISMP Tall-Man Lettering Principles 7.2 High-Risk Community/Ambulatory LASA Pairs 7.3 High-Risk Institutional/Hospital LASA Pairs & Packaging Traps

8 Chapter 8: Packaging, Expiration, Storage & Special Handling

8.1 Expiration Date Interpretation and Multi-Dose Vial Beyond-Use Dating (BUD) 8.2 Packaging Integrity, Moisture/Light Sensitivity, and FDA Recall Classes 8.3 Temperature Storage Ranges and Vaccine Cold Chain Integrity 8.4 USP <800> Hazardous Drug Identification and Handling Precautions

9 Chapter 9: NDC Conversion, Repackaging & Final Dispensing Checks

9.1 NDC 10-Digit to 11-Digit Conversion (5-4-2 Standardization) 9.2 Unit-Dose Repackaging Standards and USP <795> BUD Guidelines 9.3 Days Supply Calculations, Package Size Verification, and Final Label Matching

6.2 Insulin Formulations, Concentrations (U-100, U-500, U-200, U-300), and Pen/Vial Math

Key Takeaways Explain This Topic AI

Insulin is categorized into rapid-acting (lispro, aspart, glulisine), short-acting (Regular), intermediate-acting (NPH), and long-acting (glargine, detemir, degludec) formulations, where NPH and premixed insulins are cloudy suspensions requiring gentle inversion (never shaking).

Standard insulin concentration is U-100 (100 units/mL), whereas concentrated insulins include Humulin R U-500 (500 units/mL), Toujeo glargine U-300 (300 units/mL), Humalog lispro U-200 (200 units/mL), and Tresiba degludec U-200 (200 units/mL).

Humulin R U-500 is 5 times more concentrated than standard U-100 insulin; it carries an extreme risk of fatal hypoglycemia and must only be measured using a dedicated green-striped U-500 syringe or a dedicated U-500 KwikPen.

Insulin pen devices automatically dial the prescribed units directly regardless of concentration; withdrawing insulin from an insulin pen cartridge with an external syringe is strictly prohibited due to fatal overdose miscalculations.

Room temperature Beyond-Use Dating (BUD) varies dramatically across insulin formulations, ranging from 10 days (Humulin 70/30 pens) to 28 days (Lantus, Humalog, Novolog), 42 days (Levemir, Novolin N vials), and 56 days (Toujeo, Tresiba).

Last updated: August 2026

Insulin Formulations, Concentrations, and Delivery Math

Critical Verification Principle: Insulin is one of the top high-alert medications in both inpatient and outpatient pharmacy practice. An error in concentration selection (e.g., confusing U-100 with U-500), syringe type, or beyond-use dating can precipitate rapid, fatal hypoglycemic encephalopathy or severe diabetic ketoacidosis. Product verification requires absolute precision in pharmacokinetic matching, concentration verification, and device math.

Insulin is an endogenous peptide hormone essential for glucose homeostasis. In pharmacotherapy, synthetic recombinant human insulins and insulin analogs are formulated across diverse pharmacokinetic profiles and concentrations. Technicians performing product verification must master insulin kinetics, visual characteristics, specialized syringe markings, and concentrated delivery systems.

1. Pharmacokinetic Classification & Visual Appearance

Insulin products are classified based on their onset of action, peak therapeutic effect, and overall duration of activity. In addition to chemical structure, their physical visual appearance (clear solution vs. cloudy suspension) is a mandatory verification checkpoint.

Pharmacokinetic Class Generic Name Brand Names Onset Peak Effect Effective Duration Visual Appearance & Handling Rules

Rapid-Acting Insulin lispro; Insulin aspart; Insulin glulisine Humalog, Admelog, Lyumjev; Novolog, Fiasp; Apidra 10–30 min 30–90 min 3–5 hours Clear solution. Administer within 15 minutes before or immediately after meals. Compatible with IV infusion (Regular preferred).

Short-Acting Regular human insulin Humulin R, Novolin R 30–60 min 2–4 hours 5–8 hours Clear solution. Administer 30 minutes prior to meals. Standard insulin of choice for continuous intravenous (IV) infusions in DKA.

Intermediate-Acting NPH (Neutral Protamine Hagedorn) Humulin N, Novolin N 1–2 hours 4–12 hours 14–24 hours Cloudy suspension. Contains protamine buffer. Must be gently rolled/inverted 10 times prior to use; NEVER shake vigorously (causes foaming and protein denaturation). Never give IV!

Long-Acting (Basal) Insulin glargine; Insulin detemir Lantus, Basaglar, Semglee, Toujeo (U-300); Levemir 1–4 hours Relatively flat / peakless 24 hours (Lantus); 14–24 hours (Levemir) Clear solution. Provides flat, steady baseline glucose control. NEVER mix in the same syringe with any other insulin (acidic pH causes precipitation).

Ultra-Long-Acting Insulin degludec Tresiba (U-100, U-200) 1 hour Peakless >42 hours Clear solution. Forms multi-hexamers in subcutaneous tissue for ultra-extended, flat release.

Premixed Combinations NPH / Regular (70/30); Protamine / Lispro (75/25, 50/50); Protamine / Aspart (70/30) Humulin 70/30, Novolin 70/30; Humalog Mix 75/25, Humalog Mix 50/50; Novolog Mix 70/30 Dual onset (15–30 min) Dual peak 14–24 hours Cloudy suspension. Combines rapid/short mealtime coverage with intermediate basal coverage. First number is intermediate protamine component; second number is rapid/short component. Must roll gently before use.

Important

The Clear vs. Cloudy Rule: All rapid-acting, short-acting (Regular), and long-acting (glargine, detemir, degludec) insulins are crystal-clear solutions . If a vial or pen of Lantus, Humalog, or Regular insulin appears cloudy, discolored, or contains particulate matter, it is degraded and must be quarantined immediately. Conversely, NPH and all premixed insulins (70/30, 75/25, 50/50) are cloudy suspensions that require gentle rolling/inversion to resuspend before drawing.

2. Standard U-100 vs. Concentrated Insulin Formulations

Historically, nearly all commercial insulins were manufactured at a standard concentration of U-100 (meaning 100 units of insulin per 1 mL of fluid ). However, severely insulin-resistant patients requiring massive daily doses (often >200 units/day) require large injection volumes with U-100, causing pain, erratic subcutaneous absorption, and tissue lipohypertrophy. To address this, manufacturers developed concentrated formulations.

Insulin Formulation Concentration Relative Potency vs U-100 Volume for 50 Units Available Delivery Devices Primary Indication / Clinical Role

Standard Insulin (e.g., Humalog, Lantus, Novolog, Regular) U-100 (100 units/mL) 1x (Baseline) 0.5 mL 10 mL vials, 3 mL cartridges, 3 mL disposable pens Standard replacement therapy for Type 1 and Type 2 diabetes.

Humalog KwikPen / Lyumjev U-200 (200 units/mL) 2x as concentrated 0.25 mL 3 mL disposable KwikPen (600 units total per pen) Rapid mealtime insulin for patients requiring high mealtime doses with smaller injection volumes.

Tresiba FlexTouch U-200 (200 units/mL) 2x as concentrated 0.25 mL 3 mL disposable FlexTouch pen (600 units total per pen) Ultra-long basal insulin; delivers up to 160 units in a single injection.

Toujeo SoloStar / Max SoloStar U-300 (300 units/mL) 3x as concentrated 0.167 mL 1.5 mL SoloStar (450 units total), 3 mL Max SoloStar (900 units total) Concentrated glargine providing a more compact depot and flatter 24-hour basal release profile.

Humulin R U-500 U-500 (500 units/mL) 5x as concentrated 0.10 mL 20 mL vial (10,000 units total), 3 mL KwikPen (1,500 units total) Severe insulin resistance (>200 units/day); extreme high-alert medication.

3. Humulin R U-500: Extreme High-Alert Precautions

Humulin R U-500 is five times more concentrated than standard U-100 insulin. Because 1 unit of U-500 contains the insulin mass of 5 units of U-100 in just 0.002 mL , any dosing or calculation error produces catastrophic consequences. ┌────────────────────────────────────────────────────────────────────────┐

  • │ HUMULIN R U-500 CONCENTRATION MATH │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ • 1 mL = 500 units of insulin │
  • │ • 0.1 mL = 50 units of insulin │
  • │ • 0.01 mL = 5 units of insulin │
  • │ • 0.002 mL = 1 unit of insulin │
  • │ │
  • │ FATAL TRAP: If a nurse uses a standard U-100 syringe to draw U-500 │
  • │ insulin up to the '50 unit' mark, the patient receives 250 UNITS │
  • │ (a 5-fold massive overdose precipitating fatal hypoglycemia)! │
  • └────────────────────────────────────────────────────────────────────────┘
  • Mandatory Safeguards for Humulin R U-500

Dedicated Green-Striped U-500 Syringe: If dispensing U-500 vials, the pharmacy must ONLY dispense dedicated U-500 syringes manufactured with a green needle shield, green plunger flange, and bold green volumetric markings . The syringe is calibrated directly in 5-unit increments up to 250 units (0.5 mL). Standard U-100 syringes or tuberculin (TB) syringes must NEVER be used.

Dedicated U-500 KwikPen: The prefilled Humulin R U-500 KwikPen dials directly in 5-unit increments. The pen automatically measures the correct volume, completely eliminating mathematical conversion errors.

Patient & Caregiver Counseling: The technician must confirm that the patient has received explicit counseling from the pharmacist on using only green U-500 syringes and recognizing the green box packaging.

4. The Cardinal Pen-vs-Vial Safety Rule

A critical exam concept and real-world safety rule governs concentrated insulin pens:

Caution

The Absolute Pen Safety Mandate: Insulin pen devices (U-100, U-200, U-300, U-500) are engineered to automatically dial and deliver the exact number of UNITS dialed, regardless of the concentration inside the cartridge.

NEVER WITHDRAW INSULIN FROM A PEN CARTRIDGE WITH AN EXTERNAL SYRINGE!

Why Drawing from a Pen with a Syringe Is Fatal

If a patient or nurse inserts an external U-100 syringe into a Toujeo U-300 or Humalog U-200 pen cartridge to draw a dose:

The pen dials in actual units (e.g., dialing 30 on a U-200 pen automatically dispenses 0.15 mL, which contains exactly 30 units).

If a practitioner uses a standard U-100 syringe and draws fluid to the "30 unit mark" (which is 0.3 mL), that 0.3 mL of U-200 insulin actually contains 60 UNITS OF INSULIN (a 100% overdose).

If drawn from a Toujeo U-300 pen to the "30 unit mark" (0.3 mL), the syringe contains 90 UNITS OF INSULIN (a 300% / 3-fold overdose). ┌─────────────────────────────────────────────────────────────────────────────┐

  • │ THE FATAL EXTERNAL SYRINGE TRAP │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ Prescribed: 40 units of Toujeo (U-300 glargine) │
  • │ │
  • │ Correct Pen Method: │
  • │ Dial pen to '40' → Injects 0.133 mL → Delivers exactly 40 units. │
  • │ │
  • │ Fatal External Syringe Error: │
  • │ Draw to '40 unit' mark on U-100 syringe (0.40 mL) from Toujeo cartridge │
  • │ Math: 0.40 mL × 300 units/mL = 120 UNITS DELIVERED (3x Lethal Overdose!) │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • 5. Insulin Syringe Calibrations and Selection

When dispensing insulin vials, verifying technicians must ensure that the selected syringe barrel capacity matches the patient's individual dose to optimize measurement accuracy and visual legibility.

Syringe Size (U-100) Maximum Dose Capacity Graduation Markings Best Suited Clinical Dosing Range

0.3 mL Syringe 30 Units 0.5-unit or 1-unit markings Doses up to 30 units (ideal for pediatric, elderly, and small fractional doses)

  • 0.5 mL Syringe 50 Units 1-unit markings Doses between 31 and 50 units
  • 1.0 mL Syringe 100 Units 1-unit or 2-unit markings Doses between 51 and 100 units

Dedicated U-500 Syringe 250 Units (0.5 mL) 5-unit green markings Specifically for Humulin R U-500 vial administration only

Warning

Prohibition of Tuberculin (TB) Syringes: Tuberculin syringes are calibrated in milliliters (0.01 mL increments) rather than insulin units. Measuring U-100 or U-500 insulin in a TB syringe requires manual mathematical decimal conversion (e.g., calculating that 24 units of U-100 = 0.24 mL), which historically carries an unacceptably high rate of 10-fold decimal errors. TB syringes are strictly contraindicated for insulin measurement.

6. Storage, In-Use Beyond-Use Dating (BUD), and Temperature Limits

Insulin is a delicate protein that rapidly denatures and loses potency when exposed to excessive heat, light, agitation, or freezing temperatures.

Unopened / Stock Storage

Refrigeration: Store unopened vials and pens in the refrigerator at 2°C to 8°C (36°F to 46°F) .

Manufacturer Expiration: Unopened refrigerated insulin remains stable until the manufacturer's printed expiration date on the carton/vial.

Never Freeze: Frozen insulin undergoes irreversible peptide aggregation; any insulin that has frozen must be discarded immediately, even if thawed.

Opened / In-Use Room Temperature Beyond-Use Dating (BUD)

Once an insulin vial or pen is removed from refrigeration and punctured or placed into service at room temperature ( up to 25°C / 77°F, maximum 30°C / 86°F ), the manufacturer beyond-use date begins. Room temperature BUD varies drastically across products:

  • | Room Temp BUD | Specific Insulin Products & Delivery Forms |
  • |---|---||
  • | 10 Days | • Humulin 70/30 Pen; • Humalog Mix 75/25 Pen; • Humalog Mix 50/50 Pen |
  • | 14 Days | • Humulin N Pen; • Novolog Mix 70/30 Pen |

| 28 Days (Standard) | • Lantus (glargine U-100) Vials & SoloStar Pens; • Basaglar / Semglee (glargine U-100) KwikPens; • Humalog (lispro U-100, U-200) Vials & KwikPens; • Novolog / Fiasp (aspart) Vials & FlexTouch Pens; • Apidra (glulisine) Vials & SoloStar Pens; • Novolin N Pens; • Humalog Mix 75/25 & 50/50 Vials; • Novolog Mix 70/30 Vials; • Humulin R U-500 KwikPens |

  • | 31 Days | • Humulin R (U-100) Vials; • Humulin N (U-100) Vials; • Humulin 70/30 Vials |
  • | 40 Days | • Humulin R U-500 Vials |

| 42 Days (6 Weeks) | • Levemir (detemir) Vials & FlexTouch Pens; • Novolin R , Novolin N , & Novolin 70/30 Vials |

| 56 Days (8 Weeks) | • Toujeo (glargine U-300) SoloStar & Max SoloStar Pens; • Tresiba (degludec U-100, U-200) Vials & FlexTouch Pens |

Loading diagram... Insulin Concentration Comparison & Delivery Volume for a 60-Unit Dose